Peer-reviewed articleOpen access

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.

Paslawski W iD, Doyon D, Ekman CJ, Yngwe H, Mamula D, Zareba-Paslawska J, Beckman M, Xu ZD iD, Hökfelt T, Tiger M iD, Lundberg J iD, Svenningsson P iD

Neuropsychopharmacology : official publication of the American College of NeuropsychopharmacologyJul 7, 2026License: open accessSweden, China0 citationsDOI: 10.1038/s41386-026-02490-3

Abstract

Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

View paper Full text (PDF)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5

Europe PMC2022